Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Clinical evidence

ONWARD2

23 evidence topics · 6 sources

Objective
Location and study date
Study start and completion dates in the ClinicalTrials.gov record
FieldQuoted record
Study start (actual)“2024-08-20”
Primary completion (actual)“2025-09-23”
Study completion (actual)“2025-12-18”
First submitted“2024-09-07”
Last update posted“2026-10-28”
Completion dates estimated at registration, September 2024, superseded in June 2025
Results posting status and certification date in the ClinicalTrials.gov record
FieldQuoted record
Results“No Results Posted”
Certification/extension first submitted“2026-08-06”
Study design
Eligibility criteria
Washout for IL-12 and IL-23 agents at registration, September 2024, superseded in October 2024
Treatment
Arms and interventions in the ClinicalTrials.gov record
Study outcomes
Rationale for using PASI 75 and sPGA 0/1 response as the co-primary endpoints
Secondary outcomes in the ClinicalTrials.gov record
Secondary outcome measureMeasure descriptionTime frame
“To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast”“Proportion of patients achieving of ≥90% or 100% reduction in PASI”“24 weeks”
“To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast”“Proportion of patients achieving of ≥75% reduction in PASI”“24 weeks”
“To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast”“Proportion of patients achieving a score of 0 or 1 on sPGA”“24 weeks”
“To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast”“Change from baseline in %BSA”“24 weeks”
“To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast”“Proportion of patients achieving a score of 0 or 1 on ssPGA”“24 weeks”
“To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast”“Proportion of patients achieving a score of 0”“24 weeks”
“To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast”“Proportion of patients achieving a score of 0 or 1”“24 weeks”
“To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo”“Change from baseline in Pruritus NRS (scale is from 0 (no pain) to 10 (severe pain)).”“24 weeks”
“Proportion of patients with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)”“Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)”“24 weeks”
“To characterize the pharmacokinetics of ESK-001”“Maximum [Cmax] and minimum [Cmin] plasma concentration”“24 weeks”
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment at registration
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics
Baseline demographics and disease characteristics by arm in ONWARD2
CharacteristicEnvudeucitinib 40 mg BID, n = 433Placebo, n = 211Apremilast 30 mg BID, n = 215
Age, years, mean (SD)“48.3 (13.1)”“49.5 (13.3)”“48.0 (12.8)”
Age group, ≥65 years, n (%)“51 (11.8)”“28 (13.3)”“20 (9.3)”
Sex, male, n (%)“283 (65.4)”“135 (64.0)”“135 (62.8)”
Race, White, n (%)“388 (89.6)”“181 (85.8)”“193 (89.8)”
Race, Asian, n (%)“10 (2.3)”“10 (4.7)”“7 (3.3)”
Race, other, n (%)“35 (8.1)”“20 (9.5)”“15 (7.0)”
Weight, kg, mean (SD)“92.3 (23.8)”“91.1 (23.1)”“90.8 (19.9)”
BMI, kg/m2, mean (SD)“31.2 (7.8)”“31.1 (7.3)”“30.9 (5.9)”
Duration of disease, years, mean (SD)“19.0 (13.5)”“20.2 (14.5)”“18.7 (14.5)”
PASI, mean (SD)“20.6 (8.3)”“21.8 (9.0)”“20.4 (8.4)”
sPGA of 4, n (%)“131 (30.3)”“70 (33.2)”“53 (24.7)”
BSA % affected, mean (SD)“25.2 (14.7)”“27.3 (16.7)”“25.8 (14.1)”
DLQI, mean (SD)“10.8 (7.0)”“10.8 (6.8)”“9.7 (7.1)”
Worst pruritus NRS, mean (SD)“6.4 (2.6)”“6.4 (2.4)”“6.0 (2.7)”
Prior systemic psoriasis treatment, n (%)“213 (49.2)”“105 (49.8)”“102 (47.4)”
Baseline itch and scalp involvement by arm in ONWARD2
CharacteristicEnvudeucitinib 40 mg BID, N = 433Placebo, N = 211Apremilast 30 mg BID, N = 215
Worst pruritus NRS ≥1, n (%)“400 (92.4)”“200 (94.8)”“199 (92.6)”
Worst pruritus NRS ≥4, n (%)“345 (79.7)”“180 (85.3)”“170 (79.1)”
ss-PGA ≥3, n“285”“140”“134”
Worst pruritus NRS ≥4 and ss-PGA ≥3, n (%)“231 (81.1)”“122 (87.1)”“108 (80.6)”
Efficacy results
PASI 75, PASI 90, and PASI 100 response rates at week 16 in ONWARD2
Week 16 response, %Envudeucitinib 40 mg BID, n = 433Placebo, n = 211Apremilast 30 mg BID, n = 215
PASI 75 (co-primary endpoint)“70.4”“13.7”“38.6”
PASI 90“53.1”“4.3”“20.9”
PASI 100“27.7”“0.9”“7.9”
PASI 75, PASI 90, and PASI 100 response rates at week 24 in ONWARD2
Week 24 response, %Envudeucitinib 40 mg BID, n = 433Apremilast 30 mg BID, n = 215
PASI 75“75.1”“43.3”
PASI 90“62.1”“25.6”
PASI 100“39.5”“13.0”
Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • ONWARD2-specific results are limited to baseline characteristics and PASI 75, PASI 90, and PASI 100 rates at weeks 16 and 24 in one congress presentation. The report holds no description of the ONWARD2 analysis sets, participant disposition, patient-reported outcomes, or safety for ONWARD2 alone, and no ONWARD2 sPGA 0/1 rate.
  • The ClinicalTrials.gov record gives an actual enrollment of 862 participants; the congress presentation gives arm sizes of 433, 211, and 215.
  • The ClinicalTrials.gov record reads “No Results Posted”, with a certification/extension first submitted on 2026-08-06.
  • Asian participants made up 10 (2.3%), 10 (4.7%), and 7 (3.3%) of the envudeucitinib, placebo, and apremilast arms, and White participants 388 (89.6%), 181 (85.8%), and 193 (89.8%).
  • Baseline sPGA of 4 was recorded in 131 (30.3%), 70 (33.2%), and 53 (24.7%) participants of the envudeucitinib, placebo, and apremilast arms, and mean baseline PASI was 20.6, 21.8, and 20.4.